FTC files amicus brief on blocking generic drugs
Pharmaceutical companies that make slight modifications to their products to obstruct generic competitors engage in exclusionary conduct and should be banned, the Federal Trade Commission argued in a brief filed in...To view the full article, register now.
Already a subscriber? Click here to view full article